
We claim:

1. A compound of formula (I):



(I)

wherein

R1 is hydrogen or C_1-C_6alkyl;

R2 is hydrogen, halogen or C_1-C_3alkyl; and

R3 is hydroxyalkyl;

or a pharmaceutically acceptable salt thereof.

2. The compound of Claim 1 wherein R1 is hydrogen, R2 is hydrogen and R3 is hydroxyalkyl.

3. The compound of Claim 2 which is 2-Pyridin-2-yl-pyrimidine-5-carboxylic acid 3-5-(1-hydroxy-1methyl-ethyl)[1,2,4]oxadiazol-3-yl]benzyl amide;

4. The compound of Claim 1 where R1 is C1-C6alkyl, R2 is hydrogen and R3 is hydroxyalkyl.


5. The compound of Claim 4 selected from the group consisting of 2-pyridin-2-yl-pyrimidine-5-carboxylic acid ((S)-1-{3-[5-(1-hydroxy-1-methyl-ethyl)-1,2,4-oxadiazol-3-yl]-phenyl}-ethyl)-amide and 2-pyridin-2-yl-pyrimidine-5-carboxylic acid ((R)-1-{3-[5-(1-hydroxy-1-methyl-ethyl)-1,2,4-oxadiazol-3-yl]-phenyl}-ethyl)-amide.

6. A pharmaceutical composition comprising the compound according to Claim 1 and a pharmaceutically acceptable carrier.

7. A method for treating an allergic or inflammatory disorder in a patient in need thereof, comprising administering to the patient a pharmaceutically effective amount of the compound according to claim 1.

8. The method according to claim 7, wherein the allergic or inflammatory disorder is selected from the group consisting of allergic rhinitis, asthma, chronic obstructive pulmonary disease and age-related macular degeneration.

9. A process for preparing a compound of formula (I)



(I)

wherein

R1 is hydrogen or C_1-C_6alkyl;

R2 is hydrogen, halogen or C_1-C_3alkyl; and

R3 is hydroxyalkyl;


or a pharmaceutically acceptable salt thereof, comprising the step of reacting a compound of formula XI



XI


wherein R1, R2 and R3 are as defined in formula I,

with an acid compound of formula




in the presence of a suitable coupling reagent.

10. The process of claim 9 wherein the compound of formula I is




and the compound of formula XI is



11. The process of claim 10 wherein the suitable coupling reagent is selected from the group consisting of DMTMM, CDI, and TBTU.

12. A process for preparing a compound of formula (I)



(I)


wherein

R1 is hydrogen or C_1-C_6alkyl;

R2 is hydrogen, halogen or C_1-C_3alkyl; and

R3 is hydroxyalkyl;


or a pharmaceutically acceptable salt thereof, comprising the step of reacting a compound of formula XI



XI

wherein R1, R2 and R3 are as defined in formula I,


with an ester compound of formula




wherein R4 is C_1-C_3alkyl,

in the presence of 1,5,7-triazabicyclo[4.4.0]dec-5-ene (TBD).

13. The process of claim 12 wherein the compound of formula I is




and the compound of formula XI is



14. The process of claim 13 wherein R4 of the ester compound is CH_3.

15. A process for preparing a compound of formula (I)



(I)


wherein

R1 is hydrogen or C_1-C_6alkyl;

R2 is hydrogen, halogen or C_1-C_3alkyl; and

R3 is hydroxyalkyl;


or a pharmaceutically acceptable salt thereof, comprising the step of reacting a compound of formula XI




XI

wherein R1, R2 and R3 are as defined in formula I,


with an acid chloride compound of formula




16. The process of claim 15 wherein the compound of formula I is



and the compound of formula XI is




17. A compound of formula




or an ecid addition salt thereof.

18. A compound of formula




or an acid addition salt thereof.


19. A compound of formula



20. A compound of formula




21. A compound of formula



wherein R2 is hydrogen, halogen or C_1-C_3alkyl; and
R3 is hydroxyalkyl;
or an acid addition salt thereof.


22. The compound of claim 21 that is



;
or an acid addition salt thereof..

23. The compound of claim 22 wherein the acid salt is the hydrochloride salt.


24. A process for preparing a compound of formula



wherein R2 is hydrogen, halogen or C_1-C_3alkyl; and

R3 is hydroxyalkyl;

comprising the step of reducing an oxime compound of formula




wherein R2 is hydrogen, halogen or C_1-C_3alkyl; and

R3 is hydroxyalkyl.

Claims

1. A compound of formula (I):



(I)

wherein

R1 is hydrogen or C_1-C_6alkyl;

R2 is hydrogen, halogen or C_1-C_3alkyl; and

R3 is hydroxyalkyl;

or a pharmaceutically acceptable salt thereof.

2. The compound of Claim 1 wherein R1 is hydrogen, R2 is hydrogen and R3 is hydroxyalkyl.

3. The compound of Claim 2 which is 2-pyridin-2-yl-pyrimidine-5-carboxylic acid 3-[5-(1-hydroxy-1methyl-ethyl)-1,2,4-oxadiazol-3-yl]benzyl amide.

4. The compound of Claim 1 where R1 is C1-C6alkyl, R2 is hydrogen and R3 is hydroxyalkyl.


5. The compound of Claim 4 selected from the group consisting of 2-pyridin-2-yl-pyrimidine-5-carboxylic acid ((S)-1-{3-[5-(1-hydroxy-1-methyl-ethyl)-1,2,4-oxadiazol-3-yl]-phenyl}-ethyl)-amide and 2-pyridin-2-yl-pyrimidine-5-carboxylic acid ((R)-1-{3-[5-(1-hydroxy-1-methyl-ethyl)-1,2,4-oxadiazol-3-yl]-phenyl}-ethyl)-amide.

6. A pharmaceutical composition comprising the compound according to Claim 1 and a pharmaceutically acceptable carrier.

7. A compound according to claim 1 for use in the treatment of an allergic or inflammatory disorder.

8. A compound according to claim 7, for use in the treatment of an allergic or inflammatory disorder, wherein the allergic or inflammatory disorder is selected from the group consisting of allergic rhinitis, asthma, chronic obstructive pulmonary disease and age-related macular degeneration.

9. A process for preparing a compound of formula (I)



(I)

wherein

R1 is hydrogen or C_1-C_6alkyl;

R2 is hydrogen, halogen or C_1-C_3alkyl; and

R3 is hydroxyalkyl;


or a pharmaceutically acceptable salt thereof, comprising the step of reacting a compound of formula XI



XI


wherein R1, R2 and R3 are as defined in formula I,

with an acid compound of formula




in the presence of a suitable coupling reagent.

10. The process of claim 9 wherein the compound of formula I is




and the compound of formula XI is



11. The process of claim 10 wherein the suitable coupling reagent is selected from the group consisting of DMTMM, CDI, and TBTU.

12. A process for preparing a compound of formula (I)



(I)


wherein

R1 is hydrogen or C_1-C_6alkyl;

R2 is hydrogen, halogen or C_1-C_3alkyl; and

R3 is hydroxyalkyl;


or a pharmaceutically acceptable salt thereof, comprising the step of reacting a compound of formula XI



XI

wherein R1, R2 and R3 are as defined in formula I,


with an ester compound of formula




wherein R4 is C_1-C_3alkyl,

in the presence of 1,5,7-triazabicyclo[4.4.0]dec-5-ene (TBD).

13. The process of claim 12 wherein the compound of formula I is




and the compound of formula XI is



14. The process of claim 12 wherein R4 of the ester compound is CH_3.

15. A process for preparing a compound of formula (I)



(I)

wherein

R1 is hydrogen or C_1-C_6alkyl;

R2 is hydrogen, halogen or C_1-C_3alkyl; and

R3 is hydroxyalkyl;


or a pharmaceutically acceptable salt thereof, comprising the step of reacting a compound of formula XI




XI

wherein R1, R2 and R3 are as defined in formula I,


with an acid chloride compound of formula




16. The process of claim 15 wherein the compound of formula I is



and the compound of formula XI is




17. A compound of formula




or an acid addition salt thereof.

18. A compound of formula




or an acid addition salt thereof.


19. A compound of formula



20. A compound of formula




21. A compound of formula



wherein R2 is hydrogen, halogen or C_1-C_3alkyl; and
R3 is hydroxyalkyl;
or an acid addition salt thereof.

22. The compound of claim 21 that is



;
or an acid addition salt thereof.

23. The compound of claim 22 wherein the acid salt is the hydrochloride salt.

24. A process for preparing a compound of formula



wherein R2 is hydrogen, halogen or C_1-C_3alkyl; and

R3 is hydroxyalkyl;

comprising the step of reducing an oxime compound of formula



wherein R2 is hydrogen, halogen or C_1-C_3alkyl; and

R3 is hydroxyalkyl.